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Large meta-analysis of genome-wide association
studies identiﬁes ﬁve loci for lean body mass
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Lean body mass, consisting mostly of skeletal muscle, is important for healthy aging. We
performed a genome-wide association study for whole body (20 cohorts of European
ancestry with n= 38,292) and appendicular (arms and legs) lean body mass (n= 28,330)
measured using dual energy X-ray absorptiometry or bioelectrical impedance analysis,
adjusted for sex, age, height, and fat mass. Twenty-one single-nucleotide polymorphisms
were signiﬁcantly associated with lean body mass either genome wide (p< 5 × 10−8) or
suggestively genome wide (p< 2.3 × 10−6). Replication in 63,475 (47,227 of European
ancestry) individuals from 33 cohorts for whole body lean body mass and in 45,090 (42,360
of European ancestry) subjects from 25 cohorts for appendicular lean body mass was suc-
cessful for ﬁve single-nucleotide polymorphisms in/near HSD17B11, VCAN, ADAMTSL3, IRS1,
and FTO for total lean body mass and for three single-nucleotide polymorphisms in/near
VCAN, ADAMTSL3, and IRS1 for appendicular lean body mass. Our ﬁndings provide new
insight into the genetics of lean body mass.
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Lean body mass consists primarily of skeletal muscle, isan important contributor to physical strength, mobility,stamina, and balance1–3, and has been a very recent focus of
an effort to deﬁne “sarcopenia” (loss of muscle tissue) for clinical
care and drug development4. The determinants of adult skeletal
muscle mass have not been well characterized. It is known, for
example, that exercise produces increases in muscle mass, and
there is some evidence that protein intake is directly associated
with lean mass5. Heavier people have increased muscle mass6,
which may be due to the loading effect of increased fat mass or
may reﬂect a common genetic background between muscle and
adipose tissue7. With aging, there is a progressive loss of skeletal
muscle mass, and a concurrent increase in fatty inﬁltration and
ﬁbrosis of muscle. This loss of muscle mass may reach a critical
point at which time functional impairment and even disability
occurs8. In fact, the annual healthcare costs of sarcopenia in the
United States are estimated to be in excess of 18 billion dollars9.
As estimated from family and twin studies, lean mass is a
highly heritable phenotype with heritability estimates of
0.52–0.6010, 11. While there have been previous studies related to
the genetic background of BMI and fat mass, few studies have
searched for genes associated with lean mass12–15, 16, 17. To date,
no single-nucleotide polymorphisms (SNPs) have been found to
be associated at a genome-wide signiﬁcance level with lean mass
(p-values< 5 × 10−8)18, 19. A copy number variation located in
the GREM1 gene was reported to be associated with lean
body mass in a genome-wide association study (GWAS) of 1627
Chinese20. Guo et al.19 identiﬁed in 1627 Chinese and replicated
in 2286 European ancestry individuals, a locus near CNTF and
GLYAT genes at 11q12.1 in a bivariate GWAS for bone-size
phenotypes and appendicular lean mass. Most recently in a study
of Japanese women, the PRDM16 gene was suggested to be
associated with lean mass21.
With the advent of relatively simple, inexpensive methods of
measuring the fat and lean compartments of the body using dual
energy X-ray absorptiometry (DXA) and bioelectrical impedance
analysis (BIA), multiple cohort studies have accumulated
phenotypic information on body composition that permits large-
scale GWAS to be performed. While whole body lean mass
incorporates all of the non-fat soft tissue including the internal
organs, appendicular lean mass, estimated by DXA and BIA, may
be a better reﬂection of skeletal muscle mass22–24. To identify
genetic loci associated with whole body and appendicular lean
mass, we performed a large-scale GWAS meta-analysis in over
100,000 participants from 53 studies yielding sufﬁcient power to
identify common variants with small to moderate effect sizes.
Results
GWAS meta-analyses for discovery and replication.
Descriptions and characteristics of the study populations in
the discovery stage and the replication stage are shown in
Supplementary Tables 4 and 5 and Supplementary Note 2.8. The
age of the participants ranged from 18 to 100 years. In the GWAS
discovery set, comprising 38,292 participants for whole body
lean mass and 28,330 participants for appendicular lean mass,
a substantial excess of low p-values compared to the null
distribution was observed after genomic control adjustment
of the individual studies prior to meta-analysis: λGC= 1.076 and
λGC= 1.075, for whole body and appendicular lean mass,
respectively (Supplementary Fig. 1)
Meta-analyses were conducted using the METAL package
(www.sph.umich.edu/csg/abecasis/metal/). We used the inverse
variance weighting and ﬁxed-effect model approach.
Supplementary Table 1 shows the genome-wide signiﬁcant
(GWS) and suggestive (sGWS) results in the discovery set.
For whole body lean mass, we observed one GWS result in/near
HSD17B11 and 12 sGWS results (in/near VCAN, ADAMTSL3,
IRS1, FTO (two SNPs), MOV10, HMCN1, RHOC, FRK, AKR1B1,
CALCR, and KLF12). For appendicular lean mass, one result was
GWS (intronic SNP in PKIB) and seven were sGWS (in/near
VCAN, ADAMTSL3, HSD17B11, IRS1, FRK, TXN, and CTNNA3).
We selected 21 associations (13 for whole body lean mass and 8
for appendicular lean mass; a total of 16 discovery SNPs with 5
SNPs overlapping between the two phenotypes) (Supplementary
Table 1) to conduct a replication study in a set of 33 cohorts
comprising up to 48,125 participants of European descent for
whole body lean mass and 43,258 participants for appendicular
lean mass. Both in silico replication and de novo genotyping for
replication was conducted. Table 1 shows the results for
successfully replicated SNPs in participants of European ancestry,
Table 1 Results for the successfully replicated SNPs in discovery, replication and combined sample
SNP ID Chrom Position Closest
gene
Allele ½ EAF Discovery (n= 38,292) Replication EU
(n= 47,227)
Combined EU
(n= 85,519)
Beta SE p-value Beta SE p-value Beta SE p-value
Whole body lean mass
rs2943656 2 226830162 IRSI A/G 0.38 −0.17 0.03 2.5 × 10−7 −0.13 0.03 8.0 × 10−6 −0.14 0.02 1.5 × 10−11
rs9991501 4 88477507 HSD17B11 T/C 0.04 −0.61 0.01 2.9 × 10−8 −0.26 0.08 1.9 × 10−3 −0.39 0.07 5.8 × 10−9
rs2287926 5 82851164 VCAN A/G 0.12 0.24 0.05 8.6 × 10−7 0.15 0.04 8.5 × 10−4 0.19 0.03 7.5 × 10−9
rs4842924 15 82378611 ADAMTSL3 T/C 0.52 −0.17 0.03 1.4 × 10−7 −0.08 0.03 3.9 × 10−3 −0.12 0.02 1.4 × 10−8
rs9936385 16 52376670 FTO T/C 0.61 −0.17 0.03 1.1 × 10−6 −0.11 0.03 1.6 × 10−4 −0.14 0.02 1.4 × 10−9
SNP ID Chrom Position Closest gene Allele ½ EAF Discovery (n= 28,330) Replication EU
(n= 42,360)
Combined EU
(n= 70,690)
Beta SE p-value Beta SE p-value Beta SE p-value
Appendicular lean mass
rs2943656 2 226830162 IRS1 A/G 0.38 −0.10 0.02 1.1 × 10−6 −0.06 0.01 2.2 × 10−5 −0.07 0.01 2.9 × 10−10
rs2287926 5 82851164 VCAN A/G 0.13 0.14 0.03 8.1 × 10−7 0.08 0.02 3.5 × 10−4 0.10 0.02 4.5 × 10−9
rs4842924 15 82378611 ADAMTSL3 T/C 0.52 −0.09 0.02 1.2 × 10−6 −0.05 0.02 1.6 × 10−3 −0.06 0.01 5.0 × 10−8
All results reﬂect analyses in participants of European ancestry
No signiﬁcant heterogeneity was observed at α= 0.00625 (0.05/8)
Only mild heterogeneity was indicated in two associations for whole body lean mass when using an uncorrected threshold of α= 0.05, FTO/rs9936385 (p= 0.018, I2= 34%) and HSD17B11/ rs9991501
(p= 0.04, I2= 31%)
All results were adjusted for the following covariates: sex, age, height and fat mass (kg)
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including the discovery phase, replication phase, and the
combined results.
For whole body lean mass, joint analysis of the discovery
and replication cohorts successfully replicated ﬁve SNPs in/near
HSD17B11, VCAN, ADAMTSL3, IRS1, and FTO (p-values
between 1.4 × 10−8 and 1.5 × 10−11 and lower than discovery
p-values). Three of these ﬁve SNPs (located in/near VCAN,
ADAMTSL3, and IRS1) were also successfully replicated (p-values
between 5 × 10−8 and 2.9 × 10−10) for appendicular lean mass.
None of the eight replicated associations (ﬁve for whole body and
three appendicular lean mass) had signiﬁcant heterogeneity at
α= 0.00625 (0.05/8, Bonferroni-corrected for eight tests). Only
mild heterogeneity was indicated in two whole body lean
mass SNPs when using an uncorrected threshold of α= 0.05:
FTO (p= 0.018, I2= 34%) and HSD17B11 (p= 0.04, I2 = 31%).
For appendicular lean mass, p-values for heterogeneity were
>0.05 for all three replicated SNPs.
Supplementary Table 1 shows the results for all participants
including those of non-European descent as well. Results were
similar showing low heterogeneity using “transethnic meta-
analysis” (MANTRA)25 for inclusion of both cohorts of European
ancestry and replication cohorts with Asians or African
Americans. Heterogeneity probability values were below 0.5 for
all replicated SNPs both for whole body and appendicular lean
mass. Furthermore, in this combined analysis, except for the
VCAN locus, log10 Bayes’ factors were >6.0 and p-values were
smaller than those found in European-only ancestry analysis.
Additional analyses stratiﬁed by sex failed to identify
signiﬁcant sex-speciﬁc associations or evidence of an interaction
between SNPs and sex (Supplementary Table 2 and Supplemen-
tary Note 1). Similarly, we also found no evidence for
heterogeneity between measurement techniques (BIA vs DXA;
Supplementary Table 3 and Supplementary Note 2). Finally, we
failed to replicate previously reported candidate genes for lean
mass (Supplementary Note 2.4)
Association with other anthropometric phenotypes. We looked
for associations between the lead SNPs in the ﬁve replicated loci
and other reported anthropometric phenotypes from the GIANT
Consortium (Supplementary Table 10)26–29. There were no sig-
niﬁcant associations (p< 0.05) between the SNP in HSD17B11
and any reported phenotypes. The allele associated with
greater lean mass was associated with lower values of various
anthropometric traits for the IRS1 (hip circumference (HC), waist
circumference (WC)), VCAN (hip ratio, WC adjusted for BMI,
waist to hip ratio adjusted for BMI), and the ADAMTSL3 locus
(height, hip, and WC with the association becoming more sig-
niﬁcant for hip and waist adjusted for BMI). The replicated FTO
SNP was very signiﬁcantly associated with BMI (p= 2.7 × 10−144)
and signiﬁcantly associated with HC (p= 9.3 × 10−81) and WC
(p= 1.3 × 10−96) in the same direction as the lean mass associa-
tion (i.e., the higher lean mass allele was associated with higher
values of anthropometric traits).
Annotation and enrichment analysis of regulatory elements.
Among ﬁve replicated SNPs, rs9991501 (HSD17B11 locus) and
rs2287926 (VCAN locus) are missense SNPs. rs2287926 was
predicted as possibly damaging to the protein structure and/or
function by PolyPhen-230. Since the remaining GWAS SNPs
are non-coding, to estimate whether these SNPs are located in
regulatory elements in speciﬁc human tissue/cell types,
we performed a tissue-speciﬁc regulatory-element enrichment
analysis using experimental epigenetic evidence including DNAse
hypersensitive sites, histone modiﬁcations, and transcription
factor-binding sites in human cell lines and tissues from the
ENCODE Project and the Epigenetic Roadmap Project. As shown
in Table 2, 86 SNPs were in high LD (r2≥ 0.8) with the GWAS
lead SNP rs2943656 at the IRS1 locus. The SNPs in this locus that
were in high LD were enriched in enhancers estimated by
ChromHMM31 (permutation p-values <0.05; after multiple test-
ing corrections), especially enriched in fat and brain tissues, but
not in skeletal muscle, smooth muscle, blood and gastrointestinal
tract tissues in the ENCODE and Roadmap projects. Although the
IRS1 locus was not speciﬁcally enriched with skeletal muscle tissue
enhancers, the lead SNP rs2943656 itself at the IRS1 locus was
actually located within a histone mark-identiﬁed promoter in an
adult skeletal muscle sample and a histone mark-identiﬁed
enhancer in several muscle samples (such as muscle satellite
cultured cells, fetal skeletal muscle, skeletal muscle myoblasts, and
skeletal muscle myotubes (Supplementary Figs. 6 and 7)). Based
on the position weight matrices (PWMs) score from Chip-seq and
other sequencing resources, rs2943656 was found to possibly alter
regulatory motifs, including Irf, Foxo, Sox, and Zfp105 in skeletal
muscle tissues with a PWM score p-value <4−7(≈6.1 × 10−5)32.
For the ADAMTSL3 locus, the GWAS lead SNP rs4842924 was
located in a histone mark-identiﬁed enhancer in smooth muscle
Table 2 Tissue-speciﬁc regulatory-element enrichment analyses of the GWAS loci (GWAS SNPs and SNPs in LD with the GWAS
SNPs)
SNP ID In/near
gene
SNP functional
role
Coding variant
function by
Polyphen2
Number of
SNPs in LDa
p-valueb of tissue-speciﬁc regulatory element enrichment analysesc
in ﬁve tissuesd
Skeletal
muscle
Smooth
muscle
Fat Brain Blood Gastrointestinal
tract
rs2943656 IRS1 Intergenic 86 0.14 0.38 1 × 10−7 0.04 0.82 1
rs9991501 HSD17B11 Exonic missense Benign
(Arg283Gln)
1 NAe NA NA NA NA NA
rs2287926 VCAN Exonic missense Possibly damaging
(Gly428Asp)
5 1 × 10−7 1 × 10−7 1 × 10−7 1 × 10−7 1 0.98
rs4842924 ADAMTSL3 Intronic 87 1 × 10−7 1 × 10−7 1 × 10−7 1 × 10−7 1 0.23
rs9936385 FTO Intronic 91 0.78 0.38 0.49 0.45 1 0.51
aSNPs in LD: number of SNPs in LD (r2≥ 0.8 and MAF≥ 1%, based on CEU samples in the 1000 Genome Project) with the lead GWAS SNP in each locus
bMinimum p-value permutation tests: this analysis included all SNPs in LD with the GWS lead SNPs. Multiple testing correction was done by the minimum p-value permutation test. Permutation p-values
<0.05 are considered as statistically signiﬁcant.
cEnhancers and promoters (regulatory elements) in 25 chromatin states (retrieved from HaploReg4 database): SNPs are located within active regulatory elements, including promoter upstream TSS,
promoter downstream TSS 1, promoter downstream TSS 2, transcribed and regulatory (prom/enh), transcribed 5ʹ preferential and enh, transcribed 3ʹ preferential and enh, transcribed and weak
enhancer, active enhancer 1, active enhancer 2, active enhancer ﬂank, weak enhancer 1, weak enhancer 2, primary H3K27ac possible enhancer, poised promoter, and bivalent promoter
dSee Supplementary Note 2.6 for description of human primary cells and tissues that were included in each tissue group
eWe did not perform enrichment analysis on rs9991501 because rs9991501 has no other SNPs in LD to obtain overlapping regulatory elements
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00031-7 ARTICLE
NATURE COMMUNICATIONS |8:  80 |DOI: 10.1038/s41467-017-00031-7 |www.nature.com/naturecommunications 3
tissues (Supplementary Figs. 11 and 12). The promoter/enhancer
enrichment analysis in the ADAMTSL3 locus showed signiﬁcant
enrichments in skeletal muscle, smooth muscle, fat and brain
tissues, but not in blood and gastrointestinal tract tissues. At the
FTO locus, a few SNPs in high LD with the GWAS lead SNP,
rs2287926, were located within a group of enhancers that are
not muscle tissue-speciﬁc (Supplementary Fig. 13); therefore, no
signiﬁcant enrichment was found in any tissues listed in Table 2.
Expression quantitative trait loci. We queried existing cis-
expression quantitative trait loci (eQTLS) analyses on the ﬁve
replicated GWAS SNPs rs2943656, rs9991501, rs2287926,
rs4842924, and rs9936385 with transcripts within 2Mb of the
SNP position in skeletal muscle tissues as well as in subcutaneous
adipose, omental adipose, liver tissue, lymphocytes, and primary
osteoblasts (obtained from bone biopsies). Rs9936385 was
associated with FTO expression in skeletal muscle tissues in the
FUSION samples (p= 4.4 × 10−11) (Supplementary Table 10).
However, in sequential conditional analysis, upon addition of the
lead FTO eQTL SNP (rs11649091, association p-value with FTO
gene expression= 5.1 × 10−15), rs9936385 was no longer sig-
niﬁcantly associated (p= 0.16), whereas rs11649091 remained
signiﬁcantly associated with FTO gene expression (p= 1.9 × 10−5).
SNP rs11649091 could not be imputed using our HapMap
imputation references; thus, we did not have association results
between rs11649091 and lean mass in the present study. The
T allele of rs9936385, associated with reduced lean mass in the
present study, was signiﬁcantly associated with lower FTO gene
expression levels in the GTEx project (Supplementary Table 9
and Supplementary Fig. 14). For rs9936385, we also examined
IRX3 and IRX5 expression in skeletal muscle tissues, as recent
reports have implicated GWAS SNPs associated with obesity in
intron 2 of the FTO gene as being associated with IRX3 and IRX5
gene expression in brain33 and adipose tissue34. SNP rs9936385
was not signiﬁcantly associated with IRX3 and IRX5 gene
expression in skeletal muscle tissues. For missense SNP rs9991501
in the HSD17B11 locus, a signiﬁcant association with HSD17B11
gene expression was found in skeletal muscle from the GTEx
project (p= 1.4 × 10−4). There were no signiﬁcant GWAS SNPs in
strong LD with this one; thus conditional analyses were not
performed.
As shown in Supplementary Table 10, for GWAS lead SNP
rs2943656 in the IRS1 locus, signiﬁcant eQTLs with the IRS1 gene
expression in omental (p= 4 × 10−7) and subcutaneous fat tissue
(p= 6.44 × 10−6) were found.
Finally we found no evidence for differential expression of
our ﬁve replicated genes in young vs old muscle biopsies
(Supplementary Note 2.7 for methods and results).
Discussion
In this ﬁrst large-scale GWA meta-analysis study for lean mass
that included most of the cohorts worldwide with lean mass
phenotypes, we identiﬁed and successfully replicated ﬁve GWS
loci (in/near HSD17B11, VCAN, ADAMTSL3, IRS1, and FTO
genes) for whole body lean mass and three of these (in/near
VCAN, IRS1, and ADAMTSL3 genes) for appendicular lean mass,
both important for sarcopenia diagnosis.
This study contributes to a better understanding of the biology
underlying inter-individual variation in muscle mass, since lean
body mass consists primarily of muscle mass (especially in the
extremities). Genetic determinants of lean body mass cannot be
studied speciﬁcally by using anthropometric measures such
as height, waist circumference, hip circumferences, or BMI,
as evidenced by our ﬁnding of associations between genetic loci
and lean mass that were not observed in results from the GIANT
consortium26–29. Four novel GWS loci for lean mass phenotypes
harboring ADAMTSL3, VCAN, HSD17B11, and IRS1 genes
have biologic effects supporting their role in skeletal muscle.
Although the functional involvement of the ADAMTSL3 gene
(a disintegrin-like and metalloprotease domain with thrombos-
pondin type I motifs-like 3) remains unknown, it has been shown
to be consistently associated with adult height in large human
samples26, including individuals of African ancestry35. The gene
is expressed ubiquitously, including in skeletal muscle but the
lead GWAS SNP in this locus was not signiﬁcantly associated
with expression of ADAMTSL3 in any of the tissues examined.
One might hypothesize that our observed association between
this gene and lean mass could be a reﬂection of an allometric
relationship between muscle mass/size and body size36. Since our
analyses were adjusted for height, it is plausible that variation in
ADAMTSL3 is associated with muscle mass directly. In fact, in a
recent study that identiﬁed classes of potentially regulatory
genomic elements that are enriched in GWAS loci, the height
phenotype was almost exclusively enriched in DNAse sites in
muscle37. In our study, we observed enrichment of regulatory
genomic elements in this locus in both skeletal muscle and
smooth muscle, which may not fully support a unique role of this
gene in only skeletal muscle tissue.
Versican (VCAN) plays a role in intercellular signaling and in
connecting cells with the extracellular matrix, which also is
important for the skeletal muscle. Interestingly, VCAN facilitates
chondrocyte differentiation and regulates joint morphogenesis38,
and therefore has a wider role in the musculoskeletal health.
The GWAS SNP in the HSD17B11 locus was signiﬁcantly
associated with the HSD17B11 gene expression in skeletal muscle.
Hydroxysteroid (17-beta) dehydrogenase 11 (HSD17B11)
functions in steroid biosynthesis, and most relevant to muscle
tissue, contributes to androgen catabolic processes. Although not
much is known about how variants in this gene associate with
sex-hormone related human phenotypes, androgen metabolism is
certainly a driver of muscle tissue anabolism and catabolism.
As for the FTO locus, variants in the FTO gene, which is
known to regulate postnatal growth in mice39, have been found to
be associated with adiposity/obesity40 and related traits, such as
BMI41, metabolic syndrome/type 2 diabetes and even with
menarche42. Apart from its role in adiposity, in two recent can-
didate gene studies, SNPs in FTO were found to associate both
with DXA-derived fat and lean mass43, and in one, the associa-
tion for lean mass was only slightly attenuated after fat mass
adjustment44, similar to our results using fat mass-adjusted lean
mass. Also, FTO knockout mice have been shown to have not
only reduced fat mass, but also decrease in lean mass45. Recently,
obesity associated non-coding sequences in the FTO gene were
found to be functionally connected to the nearby gene, IRX3, by
directly interacting with the promoters of this gene33, suggesting
obesity SNPs located inside the FTO gene may regulate gene
expression other than FTO. Our GWAS lead SNP rs9936385 in
the FTO locus was in LD with the obesity GWAS SNP and
located in the same haplotype. A denser ﬁne-mapping study using
sequencing of the FTO locus with a better resolution will be
helpful in narrowing down the FTO region to identify potential
causal variant(s). The actual function of the variants and the
underlying mechanisms of FTO’s involvement in skeletal muscle
biology still need to be further elucidated by in vitro and animal
experiments.
The other body composition-related gene that was successfully
replicated is the insulin receptor substrate 1 (IRS1), which belongs
to the insulin signaling pathway and participates in growth
hormone and adipocytokine signaling pathways. Besides being
overexpressed in adipocytes, IRS1 is also highly expressed in
skeletal muscle13, IRS1 polymorphisms have been associated
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with fasting insulin-related traits46, adiposity13, and serum
triglycerides/HDL cholesterol47. Our GWAS lead SNP rs2943656
was associated with IRS1 gene expression in skeletal muscle
obtained from the GTEx project. Interestingly, another SNP,
rs2943650, near IRS1 in high LD with our lead SNP (R2= 0.854)
was previously found to be associated with percent body fat in the
opposite direction from the association that we ﬁnd with lean
mass13. The body fat percentage decreasing allele in this study
was associated with lower IRS1 expression in omental and sub-
cutaneous fat13. Another study reported an association between a
SNP in high LD (rs2943641) with IRS-1 protein expression and
insulin-induced phosphatidylinositol 3-OH kinase activity in
skeletal muscle13. Also rs2943656 was associated with obesity
traits in the GIANT Consortium; the allele associated with greater
lean mass was inversely associated with obesity traits. Further
understanding of the potential functional effects of these variants
in the IRS1 locus are needed to determine whether they have
pleiotropic and opposite effects on fat and lean tissue. The same is
true for variants in the FTO locus for which the allele that was
associated with greater lean mass was previously reported to be
associated with greater fat mass.
From the current eQTL data analysis, we have no deﬁnitive
evidence that the non-coding GWAS SNPs (or variants in high
LD) functionally inﬂuence gene expression of IRS1, HSD17B1,
and FTO in skeletal muscle. Use of a larger reference panel for
imputation in the GWAS sample, and analysis of larger tissue
expression data sets coupled with conditional analysis will help
reveal if underlying functional associations exist. It should
be emphasized that with the current data we are not able to
determine which SNPs may be functional and it is possible that
the identiﬁed lean mass variants are not driving the associations
with expression. Using ENCODE and Epigenetic Roadmap data,
we found that the GWAS SNPs (or SNPs in LD with these SNPs)
were signiﬁcantly enriched in the predicted gene regulatory
regions (in our case, enhancers) not only in skeletal muscle, but
also in smooth muscle, fat and brain tissues. With the complexity
of lean mass phenotypes, we cannot rule out the possibility that
these genes are involved in regulating lean mass biology via tis-
sues other than skeletal muscle.
Using results from the overall meta-analysis, the percent var-
iance explained by the successfully replicated SNPs was 0.23%
and 0.16% for whole body and appendicular lean mass, respec-
tively. Estimates were slightly higher when we used individual
level data from the Framingham Study cohorts (percent variance
explained of 0.97% and 0.55% for whole body and appendicular
lean mass, respectively). This relatively small percentage of
explained variance is not dissimilar to other body composition
measures such as bone mineral density of the femoral neck, for
which 63 SNPs explained 5.8% of the variance48. To estimate the
proportion of variance for lean mass explained by all genotyped
SNPs across the genome in Framingham Study participants, we
applied a GREML model implemented in the GCTA package49
with the assumption that all 550K genotyped SNPs captured
≥80% of the common sequence variance in the Framingham
Study participants who are Caucasians of European ancestry. We
estimated that the proportion of whole body lean mass and
appendicular lean mass variance explained by all genotyped SNPs
together was 43.3% (SE: 2.7%) and 44.2% (SE: 2.6%), respectively
(after adjustment for age, age2, sex, height and fat mass), sug-
gesting most of the heritability of lean mass was not detected in
the current study due to the limitations of study design (only
common variants in this study). This percent variance is similar to
the 45% of the variance explained for height using this method49.
Because of the substantial sexual dimorphism in body
composition with men having higher muscle mass compared with
women24, we performed both sex-combined and sex-stratiﬁed
analyses. We examined potential sex differences in the genetic
associations. Lean mass is a highly heritable trait and the
heritability is of similar magnitude in both genders24, 50.
No formal interaction test between SNP and sex was signiﬁcant
for any of these SNPs. Thus, our ﬁndings do not support
any substantial sex-speciﬁc genetic inﬂuence for any of the
successfully replicated lean mass SNPs. We cannot rule out
the possibility that the reported GWS SNPs are false-positive
ﬁndings, although the chance of such false positives is extremely
low due to the robustness of replication in our well-powered
study. There are also other limitations to our study. Because lean
mass is correlated with fat mass, we adjusted for fat mass to focus
our search on genes contributing to lean mass independent of
those regulating fat mass. A potential limitation with this strategy
of adjusting for fat mass is that the power to identify genetic
signals with a similar impact on lean and fat mass will be reduced.
Nevertheless, the FTO signal was found to be signiﬁcantly
associated with lean mass after fat adjustment and the direction of
this association was the same as the association with fat mass.
Since androgens have a major impact on muscle mass, it is a
limitation of the present study that the X chromosome, harboring
the androgen receptor gene, was not included in the present
meta-analysis. Another potential weakness of this study is our
decision to meta-analyze body composition results using two
different techniques (BIA and DXA). Nevertheless, the two
methods are highly correlated (r= 0.83 for Framingham cohort
participants), and by combining them power to detect GWS loci
was greatly enhanced.
In conclusion, in this ﬁrst large-scale meta-analysis of GWAS,
ﬁve GWS variants in or near the HSD17B11, VCAN, ADAMTSL3,
IRS1, and FTO genes were found to be robustly associated with
lean body mass. Three of these loci were found to be signiﬁcantly
enriched in enhancers and promoters in muscle cells, suggesting
that our signals have a potential functional role in muscle. Our
ﬁndings shed light on pathophysiological mechanisms underlying
lean mass variation and potential complex interrelations between
the genetic architecture of muscle mass, fat mass, body height and
metabolic disease.
Methods
Study summary. We focused on two phenotypes: (1) whole body lean mass; (2)
appendicular lean mass. For these two phenotypes, we performed a genome-wide
meta-analysis of the discovery cohorts (Stage I), then meta-analyzed the genotyped
discovery SNPs in replication cohorts (Stage II), followed by a combined analysis
with discovery and replication cohorts (Supplementary Fig. 1). The total sample
size for the combined analysis was just over 100,000 from 53 studies. Our primary
results are based on the ~85,000 individuals of European descent in 47 studies, as
was pre-speciﬁed. Because whole body and appendicular lean mass are correlated
with fat mass and height, analyses were adjusted for these potential confounders in
addition to sex, age, age2, and other study-speciﬁc covariates to focus our search on
genes contributing to lean mass independent of those of body height and fat mass.
Study population. The Stage I Discovery sample comprised 38,292 individuals of
European ancestry drawn from 20 cohorts with a variety of epidemiological designs
and participant characteristics (Supplementary Tables 4–6 and Supplementary
Note 2.8). Whole body lean mass was measured using DXA (10 cohorts,
n = 21,074) and BIA (10 cohorts, n= 17,218). Of the 20 cohorts, 15 consisted
of male and female subjects, while 2 had male and 3 had female subjects only.
In total, the cohorts included 22,705 women and 15,587 men. Appendicular lean
mass was estimated in 28,330 subjects from a subset of 15 cohorts (9 using DXA
and 6 using BIA).
Subjects from 33 additional studies were used for replication with a total sample
size of 63,475 individuals. Of these 63,475, the majority was of European ancestry
(n= 47,227 in 27 cohorts), and the remaining 16,248 were of African American,
South Asian, or Korean ancestry (Supplementary Table 4). All these 33 cohorts had
data for whole body lean mass. Among them, 16 studies had DXA measurements
(n= 23,718) and 17 studies had BIA measurements (n= 39,757). Twenty-ﬁve
cohorts had data for appendicular lean mass in a total of 45,090 individuals
(16 cohorts with DXA (n= 23,718) and 9 with BIA (n= 21,372)). Of these, 42,360
individuals (23 cohorts) were of European ancestry and the remaining 2730 of
African American and Korean descent. Our a priori aim was to perform replication
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in cohorts with European subjects only and to explore if adding non-European
cohorts would increase power or show evidence of heterogeneity due to ethnicity.
The Stage II Replication included cohorts with existing GWAS data that were
unavailable at the time of the Stage I Discovery, and cohorts who agreed to undergo
de novo genotyping. All studies were approved by their institutional ethics review
committees and all participants provided written informed consent.
Lean mass measurements. Lean mass was measured in all cohorts using either
DXA or BIA. DXA provides body composition as three materials based on speciﬁc
X-ray attenuation properties; bone mineral, lipid (triglycerides, phospholipid
membranes, etc.) and lipid-free soft tissue. For each pixel on the DXA scan, these
three materials are quantiﬁed. For the cohorts with DXA measures, the phenotype
used for these analyses was the lipid free, soft tissue compartment that is referred
to as lean mass, and is the sum of body water, protein, glycerol, and soft tissue
mineral mass. Two lean mass phenotypes were used: whole body lean mass and
appendicular lean mass. The latter was obtained by considering only pixels in the
arms and legs collectively, which has been demonstrated to be a valid measure of
skeletal muscle mass51.
Some of the cohorts estimated body composition using BIA, which relies on the
geometrical relationship between impedance (Z), length (L), and volume (V) of an
electrical conductor. Adapted to the human body, V corresponds to the volume of
fat-free mass (FFM) and L to the height of the subject. Z is composed of the pure
resistance (R) of the conductor, the FFM, and the reactance (Xc), produced by
the capacitance of cellular membranes, tissue interfaces and non-ionic tissues:
Z2= R2 + Xc2. A variety of BIA machines were used by the various cohorts
(summarized in Supplementary Table 5), and in some cohorts, the speciﬁc
resistance and reactance measures were not available because the manufacturers
provided only summary output on FFM. For BIA cohorts with speciﬁc resistance
and reactance measures, we used the validated equation from Kyle et al.52 with an
R2 of 0.95 between BIA and DXA to calculate the appendicular lean mass.
Stage 1: genome-wide association analyses in discovery cohorts. Genotyping
and imputation. Genome-wide genotyping was done by each study on a variety of
platforms following standard manufacturer protocols. Quality control was per-
formed independently for each study. To facilitate meta-analysis, each group
performed genotype imputation with IMPUTE53 or MACH54 software using
HapMap Phase II release 22 reference panels (CEU or CHB/JPT as appropriate).
Overall imputation quality scores for each SNP were obtained from IMPUTE
(“proper_info”) or MACH (“rsq_hat”). Details on the genotyping platform used,
genotype quality control procedures and software for imputation employed for
each study are presented in Supplementary Table 6.
Study-speciﬁc genome-wide association analyses with lean mass. In each study,
a multiple linear regression model with additive genetic effect was applied to test
for phenotype–genotype association using ~2.0 to 2.5 million genotyped and/or
imputed autosomal SNPs. Other covariates adjusted in the model included
ancestral genetic background, sex, age, age2, height, fat mass measured by the body
composition device (kg) and study-speciﬁc covariates when appropriate such as
clinical center for multi-center cohorts. Adjustment for ancestral background was
done within cohorts using principal component analyses as necessary.
Furthermore, for family-based studies, including the Framingham Study, ERF,
UK-Twins, Old Order Amish Study and the Indiana cohort, familial relatedness
was taken into account in the statistical analysis within their cohorts by: (1) linear
mixed-effects models that speciﬁed ﬁxed genotypic and covariate effects and a
random polygenic effect to account for familial correlations (the R Kinship
package; http://cran.r-project.org/web/packages/) in the Framingham Study; (2) the
GenABEL55 in the ERF and UK-Twins cohorts; (3) the Mixed Model Analysis for
Pedigrees (MMAP) program (http://edn.som.umaryland.edu/mmap/index.php) in
the Amish cohort; and GWAF, an R package for genome-wide association analyses
with family data in the Indiana cohort56.
Meta-analyses. Meta-analyses were conducted using the METAL package
(www.sph.umich.edu/csg/abecasis/metal/). We used the inverse variance
weighting and ﬁxed-effect model approach. Prior to meta-analysis, we ﬁltered out
SNPs with low minor allele frequency, MAF (<1%) and poor imputation quality
(proper_info<0.4 for IMPUTE and rsq_hat<0.3) and applied genomic control
correction where the genomic control parameter lambda (λGC) was >1.0.
We used quantile–quantile (Q–Q) plots of observed vs. expected –log10
(p-value) to examine the genome-wide distribution of p-values for signs of
excessive false-positive results. We generated Manhattan plots to report genome-
wide p-values, regional plots for genomic regions within 100 Kb of top hits, and
forest plots for meta-analyses and study-speciﬁc results of the most signiﬁcant SNP
associations. A threshold of p< 5 × 10−8 was pre-speciﬁed as being genome-wide
signiﬁcant (GWS), while a threshold of p< 2.3 × 10−6 was used to select SNPs for a
replication study (suggestive genome-wide signiﬁcant, sGWS).
Stage 2: replication. In each GWS or sGWS locus, we selected the lead SNP
with the lowest p-value for replication. In addition, GWS or sGWS SNPs that had
low-linkage disequilibrium with the lead SNPs (LD< 0.5) were also selected for
replication. Both in silico replication and de novo genotyping for replication was
conducted. In silico replication was done in 24 cohorts with GWAS SNP chip
genotyping that did not have data available at the time of the initial discovery
efforts (Supplementary Table 7). De-novo replication genotyping was done using:
KBioScience Allele-Speciﬁc Polymorphism (KASP) SNP genotyping system
(in OPRA, PEAK25, AGES, CAIFOS, DOPS cohorts), TaqMan (METSIM),
Illumina OmniExpress + Illumina Metabochip (PIVUS and ULSAM),
or Sequenom’s iPLEX (WHI) (Supplementary Table 8). Samples and SNPs that did
not meet the quality control criteria deﬁned by each individual study were
excluded. Minimum genotyping quality-control criteria were deﬁned as: SNP call
rate > 90% and Hardy–Weinberg equilibrium p > 1 × 10−4.
Meta-analysis of replication and discovery studies. In the replication stage, we
meta-analyzed results from: (1) individuals of European descent only (Rep-EUR);
and (2) all replication cohorts with multiple ethnicities (Rep-All). Likewise
we meta-analyzed results from discovery cohorts and European-descent-only
replication cohorts (“Combined EUR”) from discovery cohorts and all replication
cohorts (“Combined All”). To investigate and account for potential heterogeneities
in allelic effects between studies, we also performed “trans-ethnic meta-analysis”
using MANTRA25 in the replication sample that included all ethnic groups
(“Rep-All”) and in the combined analysis of the discovery and all ethnic groups in
the replication sample (“Combined All”).
A successful replication was considered if: (1) the association p-value in
the cumulative-meta-analysis (Combined EUR) was genome-wide signiﬁcant
(p< 5 × 10−8) and less than the discovery meta-analysis p-value; or (2) the
association p-value in the meta-analysis of replication-cohorts only (Rep-EUR) was
less than p= 0.0024 (a Bonferroni-adjusted threshold at p= 0.05/21 since there
were a total of 21 tests performed for whole body and appendicular lean mass in
Rep-EUR cohorts during replication). Using the METAL package we also estimated
I2 to quantify heterogeneity and p-values to assess statistical signiﬁcance for a total
of eight associations that were replicated in the cumulative-meta-analysis
(combined EUR, ﬁve SNPs for whole body and three for appendicular lean mass).
To estimate the phenotypic variance explained by the genotyped SNPs
in the Framingham Heart Study (FHS), we used a restricted maximum likelihood
model implemented in the GCTA (Genome-wide Complex Trait Analysis) tool
package57, 58 and adjusted for the same set of covariates included in our GWAS.
Finally, we examined associations between all imputed SNPs in/near ﬁve genes
(THRH, GLYAT, GREM1, CNTF, and PRDM16 including 60 kB up and
downstream of the gene) and lean mass, as these genes have been implicated to
have associations with lean mass in previous association studies18–20.
Annotation and enrichment analysis of regulatory elements. For coding
variants, we predicted their function by PolyPhen-2. For all variants, we annotated
potential regulatory functions of our replicated GWAS SNPs and loci based on
experimental epigenetic evidence including DNAse hypersensitive sites, histone
modiﬁcations, and transcription factor-binding sites in human cell lines and tissues
from the ENCODE Project and the Epigenetic Roadmap Project. We ﬁrst selected
SNPs in high LD (r2≥ 0.8) with GWAS lead SNPs based on the approach of
Trynka et al.59 We then identiﬁed potential enhancers and promoters in the GWAS
loci (GWAS SNPs and SNPs in LD with the GWAS SNPs) across 127 healthy
human tissues/normal cell lines available in the ENCODE Project and the
Epigenetic Roadmap Project from the HaploReg4 web browser60 using
ChromHMM31. To evaluate whether replicated GWAS loci were enriched with
regulatory elements in skeletal muscle tissue, we performed a hypergeometric test.
Speciﬁcally we tested whether estimated tissue-speciﬁc promoters and enhancers in
a GWAS locus were enriched in eight relevant skeletal muscle tissues/cell lines vs
enrichment in non-skeletal muscle tissues (119 tissues/cell lines). The permutation
with minimum p-value approach was performed to correct for multiple testing.
Permutation p-values <0.05 were considered statistically signiﬁcant. In addition,
we also performed enrichment analyses in smooth muscle tissues/cells, fat tissue,
brain, blood cells and gastrointestinal tract tissues. The eight skeletal muscle
relevant tissues/cells were excluded when conducting enrichment analyses for
other tissue types. The detailed information for tissue types and chromatin state
estimation is described in the Supplementary Materials.
cis-eQTL. We conducted cis-eQTL analyses on the ﬁve replicated GWS loci, SNPs
rs2943656, rs9991501, rs2287926, rs4842924, and rs9936385, with gene expression
within 2Mb of the SNP position. A linear regression model was applied to examine
associations between SNP and gene expression. The eQTL analyses were performed
in ﬁve studies with available human skeletal muscle tissues, including: GTEx61,
STRRIDE62, 63, a study with chest wall muscle biopsies from patients who
underwent thoracic surgery for lung and cardiac diseases64, the Finland-United
States Investigation of NIDDM Genetics (FUSION) Study65, and a study of Pima
Indians66. In addition, eQTL analyses were also conducted in studies with other
human tissues, including subcutaneous adipose67, 68, omental adipose67, 68, liver
tissue67, lymphocytes69, and primary osteoblasts70 (obtained from bone biopsies).
These ﬁve GWAS SNPs were either genotyped or imputed in each sample. The
detailed methods are described in the Supplementary Materials. Multiple testing
was corrected by using false discovery rate (FDR q-value <0.05) to account for all
pairs of SNP-gene expression analyses in multiple tissues and studies.
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